Market Research Logo

Brain Edema - Pipeline Review, H2 2016

Brain Edema - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Brain Edema - Pipeline Review, H2 2016, provides an overview of the Brain Edema (Central Nervous System) pipeline landscape.

Brain swelling is enlargement of the brain due to excessive fluid collection in the chambers, or ventricles, of the brain or the accumulation of fluid within the brain tissue itself. Cause of brain swelling includes traumatic brain injury (tbi), ischemic stroke, hemorrhages, tumors and infections (toxoplasmosis, meningitis, subdural empyema). Symptoms include headache, neck pain or stiffness, nausea or vomiting, dizziness, irregular breathing, vision loss or changes, memory loss, inability to walk, difficulty speaking, stupor, seizures and loss of consciousness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Brain Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Edema (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Edema (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Brain Edema.

Brain Edema (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Edema (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Brain Edema (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Brain Edema (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Brain Edema (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Brain Edema (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Brain Edema (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Brain Edema (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Brain Edema Overview
Therapeutics Development
Pipeline Products for Brain Edema - Overview
Pipeline Products for Brain Edema - Comparative Analysis
Brain Edema - Therapeutics under Development by Companies
Brain Edema - Therapeutics under Investigation by Universities/Institutes
Brain Edema - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Brain Edema - Products under Development by Companies
Brain Edema - Products under Investigation by Universities/Institutes
Brain Edema - Companies Involved in Therapeutics Development
FibroGen Inc
Pharmazz Inc
Remedy Pharmaceuticals Inc
Brain Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FG-4497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glyburide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMZ-2123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Aquaporin-4 for Brain Edema - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Brain Edema - Dormant Projects
Brain Edema - Product Development Milestones
Featured News & Press Releases
Jun 08, 2016: Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA
Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting
Apr 06, 2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report
Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema
Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference
Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016
Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Brain Edema, H2 2016
Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Brain Edema - Pipeline by FibroGen Inc, H2 2016
Brain Edema - Pipeline by Pharmazz Inc, H2 2016
Brain Edema - Pipeline by Remedy Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Brain Edema - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Brain Edema, H2 2016
Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report